长期服用非甾体抗炎药物与痴呆风险的关系

IF 4.3 2区 医学 Q1 GERIATRICS & GERONTOLOGY
Ilse vom Hofe, Bruno H. Stricker, M. Kamran Ikram, Frank J. Wolters, M. Arfan Ikram
{"title":"长期服用非甾体抗炎药物与痴呆风险的关系","authors":"Ilse vom Hofe,&nbsp;Bruno H. Stricker,&nbsp;M. Kamran Ikram,&nbsp;Frank J. Wolters,&nbsp;M. Arfan Ikram","doi":"10.1111/jgs.19411","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Non-steroidal anti-inflammatory (NSAID) medication could reduce dementia risk due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational studies and short-term randomized-controlled trials have been inconsistent, and duration and dose–response relationships are still unclear.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We included 11,745 dementia-free participants from the prospective population-based Rotterdam Study (59.5% female, mean age 66.2 years). NSAID use from 1991 was derived from pharmacy dispensing records, from which we determined cumulative duration and dose. We defined four mutually exclusive categories of cumulative use: non-use, short-term use (&lt; 1 month), intermediate-term use (between 1 and 24 months), and long-term use (&gt; 24 months). We determined the association with dementia risk until 2020 using Cox regression models, including NSAID use as a time-varying exposure. Models were adjusted for lifestyle factors, comorbidity, and comedication use. We repeated the analyses stratified by previously established amyloid-β lowering properties of different NSAIDs.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During an average follow-up period of 14.5 years, a total of 9520 (81.1%) participants had used NSAIDs at any given time, and 2091 participants developed dementia. Use of NSAIDs was associated with lower dementia risk for long-term users (HR [95% CI]: 0.88 [0.84–0.91]), and a small increased risk with short-term use (HR [95% CI]: 1.04 [1.02–1.07]) or intermediate-term use (HR: 1.04 [1.02–1.06]). The cumulative dose of NSAIDs was not associated with decreased dementia risk (HR for ≤ 25th percentile: 1.06 [1.03–1.09], 26–50th percentile: 1.02 [0.99–1.05], 51–75th percentile: 1.03 [0.99–1.06], &gt; 75th percentile: 0.99 [0.96–1.02]). Associations were somewhat stronger for long-term use of NSAIDs without known effects on amyloid-β than for amyloid-lowering NSAIDs (HR [95% CI]: 0.79 [0.74–0.85] versus 0.89 [0.85;0.93]).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Long-term NSAID use, but not cumulative dose, was associated with decreased dementia risk. This suggests that prolonged rather than intensive exposure to anti-inflammatory medication may hold potential for dementia prevention.</p>\n </section>\n </div>","PeriodicalId":17240,"journal":{"name":"Journal of the American Geriatrics Society","volume":"73 5","pages":"1484-1490"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgs.19411","citationCount":"0","resultStr":"{\"title\":\"Long-Term Exposure to Non-Steroidal Anti-Inflammatory Medication in Relation to Dementia Risk\",\"authors\":\"Ilse vom Hofe,&nbsp;Bruno H. Stricker,&nbsp;M. Kamran Ikram,&nbsp;Frank J. Wolters,&nbsp;M. Arfan Ikram\",\"doi\":\"10.1111/jgs.19411\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Non-steroidal anti-inflammatory (NSAID) medication could reduce dementia risk due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational studies and short-term randomized-controlled trials have been inconsistent, and duration and dose–response relationships are still unclear.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We included 11,745 dementia-free participants from the prospective population-based Rotterdam Study (59.5% female, mean age 66.2 years). NSAID use from 1991 was derived from pharmacy dispensing records, from which we determined cumulative duration and dose. We defined four mutually exclusive categories of cumulative use: non-use, short-term use (&lt; 1 month), intermediate-term use (between 1 and 24 months), and long-term use (&gt; 24 months). We determined the association with dementia risk until 2020 using Cox regression models, including NSAID use as a time-varying exposure. Models were adjusted for lifestyle factors, comorbidity, and comedication use. We repeated the analyses stratified by previously established amyloid-β lowering properties of different NSAIDs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>During an average follow-up period of 14.5 years, a total of 9520 (81.1%) participants had used NSAIDs at any given time, and 2091 participants developed dementia. Use of NSAIDs was associated with lower dementia risk for long-term users (HR [95% CI]: 0.88 [0.84–0.91]), and a small increased risk with short-term use (HR [95% CI]: 1.04 [1.02–1.07]) or intermediate-term use (HR: 1.04 [1.02–1.06]). The cumulative dose of NSAIDs was not associated with decreased dementia risk (HR for ≤ 25th percentile: 1.06 [1.03–1.09], 26–50th percentile: 1.02 [0.99–1.05], 51–75th percentile: 1.03 [0.99–1.06], &gt; 75th percentile: 0.99 [0.96–1.02]). Associations were somewhat stronger for long-term use of NSAIDs without known effects on amyloid-β than for amyloid-lowering NSAIDs (HR [95% CI]: 0.79 [0.74–0.85] versus 0.89 [0.85;0.93]).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Long-term NSAID use, but not cumulative dose, was associated with decreased dementia risk. This suggests that prolonged rather than intensive exposure to anti-inflammatory medication may hold potential for dementia prevention.</p>\\n </section>\\n </div>\",\"PeriodicalId\":17240,\"journal\":{\"name\":\"Journal of the American Geriatrics Society\",\"volume\":\"73 5\",\"pages\":\"1484-1490\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgs.19411\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Geriatrics Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jgs.19411\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Geriatrics Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jgs.19411","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:非甾体抗炎(NSAID)药物由于具有抗炎和可能降低淀粉样蛋白的特性,可以降低痴呆风险。然而,观察性研究和短期随机对照试验的结果不一致,持续时间和剂量-反应关系仍不清楚。方法:我们从前瞻性人群为基础的鹿特丹研究中纳入了11,745名无痴呆的参与者(59.5%为女性,平均年龄66.2岁)。从1991年开始使用的非甾体抗炎药来源于药房配药记录,我们从中确定了累积持续时间和剂量。我们定义了四个相互排斥的累积使用类别:不使用,短期使用(24个月)。我们使用Cox回归模型确定了到2020年与痴呆风险的关系,包括使用非甾体抗炎药作为时变暴露。模型根据生活方式因素、合并症和药物使用情况进行了调整。我们根据先前确定的不同非甾体抗炎药的淀粉样蛋白-β降低特性重复分析。结果:在平均14.5年的随访期间,共有9520名(81.1%)参与者在任何给定时间使用过非甾体抗炎药,2091名参与者出现痴呆。长期使用非甾体抗炎药与较低的痴呆风险相关(HR [95% CI]: 0.88[0.84-0.91]),短期使用(HR [95% CI]: 1.04[1.02-1.07])或中期使用(HR: 1.04[1.02-1.06])的风险略有增加。非甾体抗炎药累积剂量与痴呆风险降低无相关性(HR≤25百分位数:1.06[1.03-1.09],26-50百分位数:1.02[0.99-1.05],51-75百分位数:1.03 [0.99-1.06],bb0 75百分位数:0.99[0.96-1.02])。长期使用对淀粉样蛋白-β无已知影响的非甾体抗炎药的相关性强于降低淀粉样蛋白的非甾体抗炎药(HR [95% CI]: 0.79[0.74-0.85]对0.89[0.85;0.93])。结论:长期使用非甾体抗炎药与痴呆风险降低有关,但与累积剂量无关。这表明,长期而非密集地服用抗炎药物可能具有预防痴呆症的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-Term Exposure to Non-Steroidal Anti-Inflammatory Medication in Relation to Dementia Risk

Background

Non-steroidal anti-inflammatory (NSAID) medication could reduce dementia risk due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational studies and short-term randomized-controlled trials have been inconsistent, and duration and dose–response relationships are still unclear.

Methods

We included 11,745 dementia-free participants from the prospective population-based Rotterdam Study (59.5% female, mean age 66.2 years). NSAID use from 1991 was derived from pharmacy dispensing records, from which we determined cumulative duration and dose. We defined four mutually exclusive categories of cumulative use: non-use, short-term use (< 1 month), intermediate-term use (between 1 and 24 months), and long-term use (> 24 months). We determined the association with dementia risk until 2020 using Cox regression models, including NSAID use as a time-varying exposure. Models were adjusted for lifestyle factors, comorbidity, and comedication use. We repeated the analyses stratified by previously established amyloid-β lowering properties of different NSAIDs.

Results

During an average follow-up period of 14.5 years, a total of 9520 (81.1%) participants had used NSAIDs at any given time, and 2091 participants developed dementia. Use of NSAIDs was associated with lower dementia risk for long-term users (HR [95% CI]: 0.88 [0.84–0.91]), and a small increased risk with short-term use (HR [95% CI]: 1.04 [1.02–1.07]) or intermediate-term use (HR: 1.04 [1.02–1.06]). The cumulative dose of NSAIDs was not associated with decreased dementia risk (HR for ≤ 25th percentile: 1.06 [1.03–1.09], 26–50th percentile: 1.02 [0.99–1.05], 51–75th percentile: 1.03 [0.99–1.06], > 75th percentile: 0.99 [0.96–1.02]). Associations were somewhat stronger for long-term use of NSAIDs without known effects on amyloid-β than for amyloid-lowering NSAIDs (HR [95% CI]: 0.79 [0.74–0.85] versus 0.89 [0.85;0.93]).

Conclusion

Long-term NSAID use, but not cumulative dose, was associated with decreased dementia risk. This suggests that prolonged rather than intensive exposure to anti-inflammatory medication may hold potential for dementia prevention.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.00
自引率
6.30%
发文量
504
审稿时长
3-6 weeks
期刊介绍: Journal of the American Geriatrics Society (JAGS) is the go-to journal for clinical aging research. We provide a diverse, interprofessional community of healthcare professionals with the latest insights on geriatrics education, clinical practice, and public policy—all supporting the high-quality, person-centered care essential to our well-being as we age. Since the publication of our first edition in 1953, JAGS has remained one of the oldest and most impactful journals dedicated exclusively to gerontology and geriatrics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信